EBD segment maintained steady growth, with direct sales reaching a new all-time high
HONG KONG, Aug. 21, 2024 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global consumer wellness group, featuring a distinguished synergistic ecosystem of business building blocks and consumer-focused approach, including energy-based devices, injectables, aesthetics and digital dentistry, personal care, and more, today announced its unaudited consolidated interim results for the six months ended June 30, 2024 (the "Reporting Period").
FINANCIAL HIGHLIGHTS
Revenue was US$168.7 million, representing a decrease of 1.7%YoY.
Revenues in APAC, Europe, and Middle East and Africa were US$56.0 million, US$24.0 million, and US$15.4 million, increased by 15.5%YoY, 10.0%YoY, and 10.9%YoY, respectively. Revenue in North America was US$67.0 million, representing a decrease of 15.7% YoY.
The Energy Based Devices (EBD) segment achieved revenue of US$149.3 million, representing an increase of 1.3%YoY.
Portion of revenue derived from direct sales reached 86.1%, compared to 72.1% for the corresponding period in 2023.
Gross profit margin increased to 62.4% for the Reporting Period, up from 61.4% for the corresponding period in 2023.
The adjusted net profit was US$16.7 million, representing a decrease of 19.4% YoY.
KEY ACHIEVEMENTS
Product portfolio expanded with significant R&D achievements
Three new products were successfully launched with immediate market adoption and better-than-expected new order intake, reflecting strong customer confidence in Alma platforms.
Alma Harmony™: A new and innovative cutting-edge multi-modal anti-aging platform that was launched in North America. With FDA-cleared for over 130 indications, this product is tailored to address multiple signs of aging across all skin types and diverse demographics. Alma Harmony™ was launched in North America with immediate market adoption.
The Special Edition of Soprano Titanium™: A new and improved Alma's flagship equipment platform for hair removal delivering 20% more energy, while remaining virtually painless. It effectively treats all skin and hair types with all-in-one TrioMax™ handpiece that combines the three of the most clinically validated laser hair removal wavelengths – 755nm, 810nm and 1064nm. The product was warmly embraced by the market after its global debut.
Alma IQ™: A whole new intelligent skin analysis and consultation solution. Alma IQ™ revolutionizes the consultation process by offering a visually engaging, interactive and automatic experience while addressing the patients' skin health concerns.
Solidified Sisram injectables' global presence by the strategic partnership with Prollenium®, a Canadian premium CE and FDA approved dermal filler manufacturer, to distribute the renowned Revanesse® dermal fillers collection in several key markets including Germany, Austria, Switzerland, Australia, and New Zealand.
Profhilo®, a next-generation hyaluronic acid injectable product exclusively distributed by the Company, was granted approval by the China Hainan Medical Products Administration as a designated medical device in April 2024.
